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Abstract
Azole compounds are the primary therapy for patients with diseases caused by Aspergillus fumigatus. However, prolonged
treatment may cause resistance to develop, which is associated with treatment failure. The azole target cyp51A is a hotspot
for mutations that confer phenotypic resistance, but in an increasing number of resistant isolates the underlying mechanism
remains unknown. Here, we report the discovery of a novel resistance mechanism, caused by a mutation in the CCAAT-
binding transcription factor complex subunit HapE. From one patient, four A. fumigatus isolates were serially collected. The
last two isolates developed an azole resistant phenotype during prolonged azole therapy. Because the resistant isolates
contained a wild type cyp51A gene and the isolates were isogenic, the complete genomes of the last susceptible isolate and
the first resistant isolate (taken 17 weeks apart) were sequenced using Illumina technology to identify the resistance
conferring mutation. By comparing the genome sequences to each other as well as to two A. fumigatus reference genomes,
several potential non-synonymous mutations in protein-coding regions were identified, six of which could be confirmed by
PCR and Sanger sequencing. Subsequent sexual crossing experiments showed that resistant progeny always contained a
P88L substitution in HapE, while the presence of the other five mutations did not correlate with resistance in the progeny.
Cloning the mutated hapE gene into the azole susceptible akuBKU80 strain showed that the HapE P88L mutation by itself
could confer the resistant phenotype. This is the first time that whole genome sequencing and sexual crossing strategies
have been used to find the genetic basis of a trait of interest in A. fumigatus. The discovery may help understand alternate
pathways for azole resistance in A. fumigatus with implications for the molecular diagnosis of resistance and drug discovery.
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Introduction
Aspergillus fumigatus is a ubiquitous saprophytic mold. Although
humans inhale at least several hundred of A. fumigatus conidia per
day, it rarely causes serious medical conditions in healthy
individuals. In contrast, immunocompromised patients such as
solid organ and hematopoietic stem cell transplant recipients and
patients receiving chemotherapy are at risk of developing invasive
aspergillosis, a commonly fatal infection [1]. Additionally, A.
fumigatus is able to cause a wide range of other non-invasive
diseases including allergic syndromes and aspergilloma, many of
which require treatment with antifungal agents [1,2].
Current treatment options of Aspergillus diseases include three
classes of antifungal agents: polyenes (amphotericin B), echino-
candins (caspofungin) and azoles, the latter being the largest and
most widely used class of antifungal drugs [3,4]. Voriconazole is
the recommended first choice therapy for invasive aspergillosis
[5,6]. Itraconazole is commonly used for the treatment of chronic
and allergic conditions [2] and posaconazole is effective in
preventing invasive aspergillosis in patients with certain hemato-
logic malignancies [7,8].
Although A. fumigatus is generally susceptible to these azole
antifungals, acquired resistance is increasingly being reported over
the last few years [9–12]. Evidence is also accumulating that
patients suffering from azole-resistant Aspergillus disease may fail to
respond to therapy [11,13–19]. The most common mechanisms of
resistance in A. fumigatus are mutations in the cyp51 gene encoding
sterol 14a-demethylase, the target for azoles. Azoles inhibit this
enzyme, thereby blocking its function in the ergosterol biosynthesis
pathway, resulting in ergosterol depletion and accumulation of
toxic sterols [20]. The A. fumigatus genome contains two distinct
but closely related cyp51 (erg11) genes: cyp51A and cyp51B, each
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encoding a different protein [21]. Mutations have rarely been
detected in the cyp51B gene and have never been shown to be
related to azole resistance [4]. In contrast, certain non-synony-
mous point mutations in the cyp51A gene (for example at codons
G54, G138 and M220) correspond with azole resistance [22–24].
Other mutations responsible for azole resistance include tandem
repeats of 34, 46 and 53 bp in the cyp51A promoter region
(generally combined with mutations in the gene itself), resulting in
an increased expression of the cyp51A gene [13,25–27]. In
addition, an Aft1 transposon was found inserted 370 bp upstream
of the start codon, possibly modulating cyp51A expression as well
[28].
As is the case for A. fumigatus, azole resistance in other fungi such
as Candida may be caused by alterations and over-expression of the
azole target 14a-demethylase. Alternatively, over-expression of
drug efflux transporters that pump the toxic azoles out of the cell
have also been related to resistance in Candida [29,30]. A. fumigatus
contains several efflux pumps of the ATB-binding cassette (ABC)
family and the Major Facilitator Superfamily (MFS) [31].
Although some of these transporters have been suggested to
reduce azole susceptibility [31–35], none of them has been proven
to play a direct role in resistance yet [28]. The question thus
remains whether efflux transporters play an active role in azole
resistance in A. fumigatus [34,36]. An alternative azole resistance
mechanism in Candida is a defective sterol D5,6-desaturase, encoded
by the erg3 gene. This allows the accumulation of less toxic sterols
in the presence of azole antifungals [29,31,37]. However, the erg3
genes have never been implicated in azole resistance in A. fumigatus
[37].
Today, an increasing number of azole-resistant isolates are
being reported without alterations in the cyp51A gene or promoter
region [9]. However, no alternate resistance mutations have yet
been found in clinical A. fumigatus isolates. Attempts to find new
genes involved in azole resistance included determining expression
levels of specific transporter genes [33–35,38] and disruption,
duplication, or truncation of a specific gene of interest followed by
analysis of antifungal susceptibility in the recombinant [39–45].
Here, we apply a new strategy to unravel the resistance
mechanism using a set of four sequentially isolated isogenic
clinical A. fumigatus isolates that acquired an azole resistant
phenotype during prolonged treatment. The isolates were
obtained from a patient with chronic granulomatous disease
(CGD) as described in detail in a previous study [46]. The first two
isolates were susceptible to azole antifungals, but the last two
isolates were azole resistant and the patient failed azole-
echinocandin combination therapy. As the A. fumigatus isolates
did not contain any mutations in the cyp51A gene or its promoter
region, this set of isolates offered a unique opportunity to study the
de novo acquisition of non-cyp51A azole resistance mutations. Our
strategy included whole genome sequencing, sexual crossing
experiments and gene replacements to identify the gene respon-
sible for the observed resistance.
Materials and Methods
Origin and characterization of A. fumigatus isolates
The patient, origin of the isolates, and characterization of the
isolates were described in detail in a previous publication [46]. The
patient was a 21 year-old male with CGD. Due to a pulmonary
infection caused by A. fumigatus, he was treated with multiple
courses of antifungal therapy including caspofungin, voriconazole
and a combination of the two. After relapse of the infection half a
year later various treatment regimens were implemented including
voriconazole, caspofungin/voriconazole combination therapy and
caspofungin/posaconazole combination therapy. During this
relapsing infection various respiratory samples were taken under
routine care and four A. fumigatus isolates were obtained,
designated isolates 1 through 4 (Figure 1). Unfortunately, despite
antifungal treatment it was not possible to eliminate the fungus
and the patient died from his pulmonary infection.
In vitro susceptibility testing of the patient isolates was performed
using the EUCAST broth microdilution reference method [47].
Results were interpreted using the previously proposed break-
points [12]. DNA was isolated and STRAf 3A, 3B, 3C, 4A, 4B,
and 4C microsatellite genotypes were determined [48]. The
cyp51A and cyp51B coding genes and promoter regions were
amplified and sequenced as described before [48]. Sequences of
the four patient isolates were aligned to identify any sequence
differences in cyp51A and cyp51B.
Complete genome sequencing and assembly
In order to unravel the resistance mechanism, isolates 2 and 3
(isolated 17 weeks apart, directly before and after the onset of azole
resistance) were selected for complete genome sequencing
(Figure 1). The isolates were cultured in liquid medium and after
harvesting and drying mycelial mats, DNA was isolated as
described elsewhere [49]. The Illumina Paired-End DNA
sequencing Sample Prep Kit (cat #1001809) was used to process
the DNA samples. Fragmentation of the DNA by nebulization,
ligation of sequencing adapters and PCR amplification of the
resulting product was performed according to the Illumina
protocol Preparing Samples for Paired-end Sequencing (1005063
Rev. A). The quality and yield after sample preparation was
measured with Lab-on-a-Chip analysis. The size of the resulting
product was consistent with the expected size of approximately
300 bp after excision from an agarose gel. DNA sequencing using
the Genome Analyzer II (Illumina) was performed according
manufacturer’s protocols. Two sequencing reads of 36 cycles each
using the Read 1 sequencing and Read 2 sequencing primers were
performed with the flow cell. Sequencing data are available at the
Sequence Read Archive (SRA) at http://www.ebi.ac.uk/ena/
data/view/ under accession number ERP001097. The two
complete A. fumigatus genomes that are publically available (clinical
isolates Af293 and A1163 [50,51]) were used as reference
sequences to aid the genome assembly. Assembly was done using
Maq [52] with default parameters, taking into account the paired-
end nature of the reads.
Prioritization and validation of potential mutations
From the complete genome sequencing data, non-synonymous
mutations were selected in isolate 3 (resistant) relative to isolate 2
(susceptible) and both reference isolates Af293 and A1163
(susceptible). Many of these mutations were expected to be
unreliable because of low sequencing depth or low quality of the
Maq consensus assembly. Potential mutations were prioritized
based on the product of the Maq assembly quality scores in the
susceptible and resistant assembly (further referred to as ‘‘product
quality score’’). As we did not know a priori what cutoffs to use,
mutations with the highest product quality scores were selected for
confirmation by conventional PCR and Sanger sequencing.
Moreover, potential mutations with lower product quality scores
were also validated for proteins potentially important in azole
resistance (e.g. transporters), or if they occurred in the genomic
vicinity of more reliably called mutations and could be validated in
one sequencing experiment. For the selected mutations, primers
were designed (Table 1) and used to amplify and sequence isolates
2 and 3 first. For confirmed mutations, isolates 1 and 4 were
subsequently amplified and sequenced.
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Sexual reproduction and analysis of the progeny
The mating type of the isolates was determined as described
before [53]. Isolates 1, 2, 3 and 4 were each crossed with isolate
47–169, a highly fertile environmental A. fumigatus isolate (kindly
provided by C.M. O’Gorman and P.S. Dyer, School of Biology,
University of Nottingham, Nottingham, UK). Mating experiments
were performed on oatmeal agar plates (Difco Oatmeal agar) and
inoculation was performed as described previously [54]. Plates
were sealed with Parafilm and incubated at 30uC in the dark.
Crosses were examined weekly and when cleistothecia developed,
ascospore suspensions were obtained as described before [54]. The
suspensions were heated at 70uC for one hour to prevent the
germination of asexual spores [54]. Then small aliquots of the
suspensions were plated onto Sabouraud agar plates and
incubated for two days at 28uC. Germinating ascospores were
transferred to Sabouraud agar slants and grown at 28uC for five
days. The progeny were tested for their susceptibility to azoles as
described above and DNA was isolated as described elsewhere
[48]. The DNA was used to check for the presence or absence of
the confirmed mutations by PCR and sequencing, using the same
primers as used for validation (Table 1). In addition, from a
selection of the progeny the microsatellite genotype was deter-
mined [48].
Growth kinetic assay
Part of the progeny was selected to evaluate growth over time.
For that, conidia were suspended in 0.1% Tween-20. Suspensions
were adjusted to 1–4.2*106 conidia/ml and diluted 1:10 in water.
100 ml thereof was added to 100 ml of double strength RPMI 2%
glucose medium in three individual wells of a microtiter plate. The
plates were incubated at 37uC for 12 h inside a plate reader. The
optical density (OD) at 450 nm was automatically recorded for
each well every 30 minutes without shaking. For each time point
the OD of the triplicate was averaged and the changes in OD over
time were used to generate growth curves. The maximum growth
per hour during the exponential section of the curve was averaged
for the susceptible and resistant progeny and to test whether
differences where significant, student’s t-test was applied (one-
tailed, heteroscedastic).
RNA isolation and cyp51A expression
A selection of the progeny and parental isolates were subjected
to cyp51A expression analysis. The isolates were cultured twice and
used for separate total RNA isolation. cDNA amplification and
RT-PCR for cyp51A and actin expression levels were performed as
described before [46]. The change in gene expression was
determined using the cyp51A/actin ratio.
Transformations
Gene replacement experiments were performed as described
before [22,26]. Briefly, DNA fragments of the six genes with
mutations (Table 2) were obtained by PCR amplification using
genomic DNA of the first resistant isolate 3. As a positive control, a
fragment with a mutation in cyp51A known to be correlated with
azole resistance (the cyp51A G54E substitution in clinical isolate
AF-72 [22]), was amplified. The primers used to amplify the six
genes as well as the cyp51A gene for the positive control are shown
in Table 2. All primers were designed to include the complete
gene, except for alpha-aminoadipate reductase large subunit
(reference Af293 gene AFUA_4G11240 and A1163 gene
AFUB_068270). Because of the large size of this gene, primers
were designed approximately 1000 bp on both sides of the
mutation. The PCR products were used for homologous gene
replacement by electroporation into the azole susceptible isolate
akuBKU80 [26,55]. Transformation mixtures were spread-plated on
minimal-medium plates containing itraconazole (0.5 to 4 mg/l) to
select for resistant recombinants. After three days of incubation at
37uC colonies were subcultured for further investigation. DNA
was isolated and the recombinants were analyzed for the presence
of the mutation by using the corresponding primers listed in
Table 1. In successful recombinants, the complete mutant gene
(primers Table 2) and the cyp51A gene and promoter region (as
described above) were sequenced to ensure no other mutations
were introduced. The susceptibility profiles of the successful
recombinants (two recombinants were selected for each mutation)
and the transformation recipient isolate akuBKU80 were determined
as described above.
HapE sequencing in resistant isolates without cyp51A
mutations
Our fungal culture collection contains A. fumigatus clinical
isolates from patients admitted to our hospital, as well as
environmental isolates and isolates sent to our laboratory for
identification, in vitro susceptibility testing, or research purposes.
Only accredited scientists in our laboratory have access to the
fungal collection. The collection was searched for isolates resistant
to one or more azoles but without any cyp51A gene mutations
known to be involved in resistance. Of these isolates hapE was
amplified by PCR and subsequently sequenced (primers Table 2).
Gene sequences were compared with isolate 2 to detect any
mutations.
Figure 1. Relapsing infection with A. fumigatus in a CGD patient. During the course of the disease, four A. fumigatus isolates were obtained.
Sampling dates of isolates 1 through 4 are indicated. S indicates susceptibility to azoles and R indicates resistance. Minimum inhibitory
concentrations (MICs) for itraconazole, voriconazole, and posaconazole are also shown. The patient was treated with voriconazole monotherapy
(week 267 to +12), caspofungin+voriconazole combination therapy (week +12 to +90) and caspofungin+posaconazole combination therapy (week
+90 to +134). Plasma concentrations at week 86 (voriconazole) and weeks 99, 105, and 123 (posaconazole) are also indicated. The patient died from
the pulmonary infection at week 134 [46].
doi:10.1371/journal.pone.0050034.g001
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Results
Characterization of the isolates
The azole minimum inhibitory concentrations (MICs) of the
four isolates obtained during the course of the disease in a CGD
patient are shown in Figure 1. According to the suggested
breakpoints [12], isolates 1 and 2 were azole susceptible, while
isolate 3 and 4 were resistant to both itraconazole and
voriconazole and had an intermediate susceptibility to posacona-
zole. The isolates did not have any nucleotide differences in their
cyp51A and cyp51B genes and promoter regions (results not shown)
and microsatellite genotyping showed that the four isolates had
identical genotypes and were thus isogenic (results not shown).
Table 1. Validation of potential mutations identified in the complete genome sequence of isolate 3 relative to isolate 2 as well as
both reference strains.
Product
quality
score
Gene
(abbreviated) Gene ID in Af293/A1163 Primer ID Primer sequence (59-39)
Result of
validation
5670 hypothetical AFUA_2G02180/AFUB_019270 411.33 GCATCACCAAAACACAGTGG correct
411.34 GGCAAATCTCCCAAGATTGA
4320 erg6 AFUA_4G03630/AFUB_099400 411.19 GTATCGAGCTGGGTGATGGT correct
411.20 AATACATGGGCGTGAAGAGC
3780 hapE AFUA_6G05300/AFUB_092980 411.13 CCGCGACATACTAACGACCT correct
411.14 GCTGTCCCAGAGAACCGTAA
3744 erg25 AFUA_4G04820/AFUB_098170 411.11 CCCAAAAAGGCAAGAAATGA correct
411.12 TCCGTTTGGACCATGATGTA
3648 alpha-amino AFUA_4G11240/AFUB_068270 411.35 CGGTTCTGAGGGTAGACCAA correct
411.36 GAAGCCCTCCTGGCTAGAGT
3600 C2H2 finger AFUA_5G07960/AFUB_055490 411.37 ACTTTGGGCTTTTGTTGTGG correct
411.38 GGAAGCAAGGTGGTTCTCAA
2052 origin recognition AFUA_8G04240/AFUB_083310 411.92 GGTCCCTTGTGTGAAGCAAT incorrect
411.93 GTCCCCCAGTCTTTTGGAAT
2046 hypothetical AFUA_5G09590/AFUB_057140 411.27 GTGGTTGATTGCAGGAGGTT incorrect
411.28 AAGCAGTCGATTCGCAGACT
1701 hypothetical AFUA_1G04630/AFUB_004980 411.29 CCCTGTCAGGTGATGTCCTT incorrect
411.30 AGGAACGTCATTGCGGATAC
….. ….. ….. ….. ….. …..
1596 MRS7 family AFUA_3G08230/AFUB_040880 411.25 GCTTTTCTTGGCTGTTCGAG incorrect
411.26 GTGGACTCGCTCTCTGTTCC
1008 MRS7 family AFUA_3G08230/AFUB_040880 411.25 GCTTTTCTTGGCTGTTCGAG incorrect
411.26 GTGGACTCGCTCTCTGTTCC
840 MFS transporter AFUA_6G06680/AFUB_072610 411.15 AGTGCCGCTGAAGATCAGTT incorrect
411.16 ATGGACGGAAAACAGACGAG
720 hypothetical AFUA_1G04630/AFUB_004980 411.29 CCCTGTCAGGTGATGTCCTT incorrect
411.30 AGGAACGTCATTGCGGATAC
348 hypothetical AFUA_2G14620/AFUB_030250 411.23 GCAGTGGACTCATCCTCCTC incorrect
411.24 GTGAAGCAGTCCCTCCTCTG
348 hypothetical AFUA_1G04630/AFUB_004980 411.29 CCCTGTCAGGTGATGTCCTT incorrect
411.30 AGGAACGTCATTGCGGATAC
69 AtrD AFUA_4G08800/AFUB_065900 411.9 TACAAGGCCGAACAAAATCC incorrect
411.10 TCAGACGAGTGTTGGACCAG
45 MFS transporter AFUA_6G06680/AFUB_072610 411.15 AGTGCCGCTGAAGATCAGTT incorrect
411.16 ATGGACGGAAAACAGACGAG
42 RTA1 domain AFUA_5G01310/AFUB_049810 411.17 GACGCTGACCGTGTACAGAA incorrect
411.18 GTCTGCTCCTTCTGCTTGCT
Potential mutations were prioritized using the product quality score (see Methods). Primers used for amplification and sequencing are indicated. The nine highest
quality scores (above ‘…..’) as well as several mutations with lower scores (below ‘…..’) were validated. ‘Correct’ indicates that the mutation found by complete genome
sequencing was validated using conventional PCR and sequencing methods; ‘incorrect’ indicates isolate 3 did not differ from isolate 2.
doi:10.1371/journal.pone.0050034.t001
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Genome sequencing, assembly and validation of
potential mutations
As no cyp51A and cyp51B mutations developed, a new, unknown
resistance mutation must have emerged during therapy. Due to
the isogenic nature of the isolates, we anticipated that the most
straightforward approach to identify this resistance mechanism
would be by complete genome sequencing of isolates 2 and 3
(isolated directly before and after the onset of azole resistance).
The volume of sequence data obtained using Illumina technology
included 8,611,525 36-nt read pairs for isolate 2 and
4,808,633 36-nt read pairs for isolate 3. The total sequence
volume was 620,029,800 nt (isolate 2) and 346,221,576 nt (isolate
3). After reference-guided assembly, the sequence coverage of
isolate 2 was 93.7% (mapped against Af293) and 94.9% (mapped
against Af1163). For isolate 3 this was 93.6% (mapped against
Af293) and 94.8% (mapped against Af1163). The average
sequencing depth was 20.3 reads for isolate 2 and 11.5 for isolate
3. Sixty-nine potential mutations were identified in resistant isolate
3 that were non-synonymous relative to both the susceptible isolate
2 and both reference isolates Af293/A1163 (Table S1). The
potential mutations were then prioritized based on their product
quality scores. Mutations with the highest scores as well as a
selection of genes with lower scores were validated by PCR and
Sanger sequencing. Table 1 shows that only the six mutations with
the highest product quality scores could be confirmed, the other
mutations were false-positive calls. Subsequent testing of isolate 1
and 4 confirmed the presence of these six non-synonymous
mutations in both resistant isolates 3 and 4 relative to the
susceptible isolates 1 and 2 (Table 3).
Sexual reproduction and analysis of the progeny
To elucidate which of the six mutations was the cause of
resistance, sexual crosses were performed. Note that this approach
would also identify potential combinations of mutations if two or
more mutations were together responsible for the resistant
phenotype. Isolates 1 to 4 were of mating type MAT1-2 and
were crossed with 47–169, an isolate of the opposite mating type
MAT1-1. After six weeks of incubation, cleistothecia appeared on
the agar plate. Ascospore progeny were isolated and subcultured.
Ten (for isolates 1 and 2), forty (for isolate 3) and twenty (for isolate
4) progeny isolates were randomly selected for susceptibility testing
and azole resistant isolates were present in the progeny of isolates 3
and 4, but not in the progeny of isolates 1 and 2 (Table 4). The
resistant progeny all exhibited a MIC of .16 mg/l for itracon-
azole. In addition, these isolates showed elevated MICs for
voriconazole and posaconazole, similar to those observed in
patient isolates 3 and 4 (results not shown). In addition, a minority
of the progeny of the resistant isolates 3 and 4 exhibited an altered
susceptibility phenotype for itraconazole, referred to as trailing
effect [56].
The forty progeny of isolate 3 were screened for the presence of
the six mutations validated in the whole genome sequencing
analysis. All mutations were present in the susceptible as well as in
the resistant progeny, except for the mutation in the hapE gene
which was only present in resistant isolates. Furthermore, Table 5
shows that all resistant progeny of isolate 3 and 4 contained the
hapE mutation while the other mutations were only present in a
part of the resistant progeny. Microsatellite typing (Table 6)
showed that twelve out of the thirteen resistant progeny (92%) had
a unique microsatellite genotype, indicating that unique germi-
nating ascospores harboring the resistance mutation were isolated
and not a single clone of resistant progeny. Taken together, these
results strongly suggest that the mutation in hapE caused the
observed resistant phenotype.
Sixteen of the progeny as well as both parental isolates (isolate 3
and 47–169) were selected to determine in vitro growth curves
(Figure S1). As can be observed in Figure 2, growth rate for
susceptible progeny was significantly higher compared to the
resistant progeny (p = 0.015). In order to determine if the cyp51A
expression level of progeny containing the HapE substitution was
altered, RT-PCR experiments were performed. A ,1.5-fold
induction of the transcriptional profile of the hapE-containing
progeny isolate compared to two susceptible progeny isolates was
found (Figure 3).
Transformations
Homologous gene replacement studies with the six mutated
genes from isolate 3 were performed using cyp51A G54E as a
Table 2. Primers used to amplify the six validated genes as well as cyp51A (positive control).
Gene
(abbreviated) Gene ID reference isolates Af293/A1163 Primer ID
Forward/reverse
primer Primer sequence (59-39)
hypothetical AFUA_2G02180/AFUB_019270 411.55 forward CTTTTGACATTTCCATATCAGTCCT
411.56 reverse TGACTATCTGTCACAATGGTTGTTC
erg6 AFUA_4G03630/AFUB_099400 411.39 forward TTTCAAGATTGTGATCTTGTGGATA
411.40 reverse GACAGCCACGTCTATAAGTTTAGGA
hapE AFUA_6G05300/AFUB_092980 411.47 forward CTCTCGCGATACATTACTGTTGTTT
411.48 reverse AGTATACTCGTTAACCTGCCAATGA
erg25 AFUA_4G04820/AFUB_098170 411.43 forward TTCAACACCCAGTTGTCTCATACTA
411.44 reverse CTGTCATCGATTTATGATAGCAGTG
alpha-amino AFUA_4G11240/AFUB_068270 411.57 forward GTATGTGGTCCTGTCGTTCATTC
411.58 reverse GGCAGAATCATCATCCTTGAG
C2H2 finger AFUA_5G07960/AFUB_055490 411.53 forward CGGTACCTTTACTGATCACTTTGAA
411.54 reverse GCTTCGTTTCACTCAATTCTATTTC
cyp51A AFUA_4G06890/AFUB_063960 365.1 forward ATGGTGCCGATGCTATGG
365.2 reverse CTGTCTCACTTGGATGTG
doi:10.1371/journal.pone.0050034.t002
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positive control (Table 2). After selection on itraconazole-
containing medium, successful recombinants were only obtained
from the positive control cyp51A and from candidate resistance
gene hapE (two recombinants each, Table 7). Subsequent
sequencing of the complete cyp51A gene and promoter region
and the hapE gene showed no additional mutations, indicating that
only the P88L- (HapE) or the G54E- (Cyp51A) causing mutation
was introduced by the homologous gene replacement. The positive
control substitution G54E in Cyp51A is known to cause resistance
to itraconazole and posaconazole [22,33,57–58], and indeed both
recombinants showed resistance to itraconazole and posaconazole.
Moreover, both HapE P88L recombinants showed resistance to
itraconazole with an MIC of .16 mg/l, as was also observed in
patient isolates 3 and 4 (cf. Figure 1 and Table 7). As observed in
the patient isolates, the voriconazole and posaconazole MICs
increased two dilution steps from 0.25 to 1 and from 0.032 to
0.125, respectively (cf. isolates 2 and 3 in Figure 1). These results
show that the HapE P88L substitution is the only one of the six
mutations in isolate 3 capable of conferring the azole resistant
phenotype.
HapE sequencing in resistant isolates without cyp51A
mutations
Our collection contained eleven resistant A. fumigatus isolates
without cyp51A mutations known to cause resistance. Eight were
clinical isolates and the remaining three isolates were of
environmental origin. Although some of the isolates did show
polymorphisms in intronic regions of the gene, we never observed
the mutation resulting in P88L or any other mutation within the
exonic regions.
Discussion
In our study the whole genome sequencing strategy was used to
identify a resistance mutation that arose as a de novo mutation in a
CGD patient with chronic fibrotic pulmonary aspergillosis caused
by A. fumigatus. We selected two A. fumigatus isolates, taken just
before and just after the transition from a susceptible to an azole-
resistant phenotype. Although the resistant strain (isolate 3) was
recovered only 17 weeks after the susceptible strain (isolate 2), we
identified no less than six non-synonymous mutations. Moreover,
if we use the validated product quality score as a reliable cutoff
(3,000), we found 16 additional mutations, bringing the total
number of mutations to at least 22 (Table S2). These included five
mutations in non-coding regions and 11 cases where the resistant
strain was synonymous to the susceptible reference genomes A.
fumigatus Af293 and A. fumigatus A1163 and thus unlikely to be
responsible for the resistant phenotype. This may indicate that A.
fumigatus undergoes many genetic changes during human infection,
possibly as a response to the stressful environment. Potentially, the
resistant strain diverged from the dominant susceptible lineage
even before the last susceptible strain was isolated. This minority
strain may have been accumulating neutral or slightly deleterious
mutations before finally the resistance causing mutation allowed it
to dominate the A. fumigatus population in the CGD patient.
Because we identified more than one non-synonymous muta-
tion, we chose sexual crossing as an additional selection method.
After crossing the patient isolates with an azole susceptible isolate
that did not contain any of the six mutations, the mutation in hapE
was identified as the most likely cause of azole resistance as this
was the only mutation present in all resistant progeny. Subsequent
Table 3. The six confirmed non-synonymous mutations, together with results of complete genome sequencing and validation.
Gene function Protein ID Af293/A1163
Nucleotide in
complete genome
sequence isolate 2/3
Validated
nucleotide in
isolate 1/2/3/4
Amino acid
substitution
Conserved hypothetical protein AFUA_2G02180/AFUB_019270 C/T C/C/T/T S219L
Sterol 24-c-methyltransferase,
putative (Erg6)
AFUA_4G03630/AFUB_099400 T/G T/T/G/G W320G
CCAAT-binding factor complex
subunit HapE
AFUA_6G05300/AFUB_092980 C/T C/C/T/T P88L
C-4 methyl sterol oxidase,
putative (Erg25)
AFUA_4G04820/AFUB_098170 G/A G/G/A/A W218*
Alpha-aminoadipate reductase
large subunit, putative
AFUA_4G11240/AFUB_068270 T/C T/T/C/C F481S
C2H2 finger and ankyrin
domain protein, putative
AFUA_5G07960/AFUB_055490 T/A T/T/A/A Y347*
*refers to a premature stop codon.
doi:10.1371/journal.pone.0050034.t003
Table 4. Distribution of susceptible and resistant isolates in the sexual crossing progeny of isolate 47–169 and each of the four
isolates in this study.
Phenotype Progeny isolate 1 Progeny isolate 2 Progeny isolate 3 Progeny isolate 4
Susceptible 10 (100%) 10 (100%) 25 (63%) 11 (55%)
Trailing-endpoint itraconazole - - 8 (20%) 3 (15%)
Resistant - - 7 (18%) 6 (30%)
Total 10 (100%) 10 (100%) 40 (100%) 20 (100%)
doi:10.1371/journal.pone.0050034.t004
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gene replacement experiments provided the final proof that the
HapE P88L substitution was the cause of the resistance phenotype
observed.
With respect to the sexual reproduction experiment, part of the
progeny of isolates 3 and 4 exhibited trailing growth (partial
inhibition of growth over an extended range of antifungal
concentrations [59]) in the presence of itraconazole. However,
these trailing isolates did show clear susceptible MIC endpoints for
voriconazole and posaconazole. Trailing endpoints caused prob-
lems when testing Candida spp. with azoles as well, but animal
models and clinical experience argue that trailing endpoints do not
indicate true resistance [56,60–61], suggesting that the progeny
with trailing endpoints for itraconazole might not be truly
resistant.
Furthermore, we noted that after sexual reproduction, only 18–
30% of the progeny contained the hapE mutation instead of the
expected 50%. Using in vitro growth kinetics in fluid medium, it
was previously shown that the resistant isolates 3 and 4 have a
significantly reduced growth rate and especially delayed germina-
tion compared to susceptible isolates 1 and 2, possibly associated
with the resistance mechanism [46]. Therefore we hypothesized
that the lower than expected recovery rate of the hapE mutation in
the progeny might be due to slow germination, as we isolated the
germinated sexual spores based on their growth on the medium
and not by randomly selecting ascospores by using the microscope.
Possibly only the faster germinating spores were collected resulting
in a lower percentage of the slower germinating, resistant (hapE
mutated) progeny. Determination of the in vitro growth curves
confirmed a significant decrease in growth rate of azole resistant
compared to azole susceptible progeny (Figure 2 and Figure S1).
Furthermore, we could speculate that the resistance mechanism is
indeed associated with loss of fitness (alteration of growth and
virulence) observed in the resistant isolates, as suggested before
[46]. We presume that the resistant isolates described here are
disadvantaged in the absence of azoles as a consequence of the
hapE mutation. In contrast, for isolates with mutations in cyp51A,
there is no evidence of fitness loss in vivo [Mavridou E, Meletiadis J,
Arendrup MC, Melchers WJ, Mouton JW, Verweij PE. Impact of
CYP51A mutations associated with azole-resistance on in vitro
growth rates and in vivo virulence of clinical Aspergillus fumigatus
isolates. 20th European Congress of Clinical Microbiology and
Infectious Diseases (ECCMID), Vienna, April 2010; abstract
O345].
Remarkably, two of the five other validated mutations were
situated in genes involved in the ergosterol biosynthesis pathway
(i.e. erg6 and erg25). A. fumigatus contains two potentially redundant
copies of these genes (erg6: AFUA_4G03630/AFUB_099400 and
AFUA_4G09190/AFUB_066290; erg25: AFUA_4G04820/
Table 5. Resistant progeny of crosses 47–169 x isolate 3 and 47–169 x isolate 4: results of susceptibility testing and mutation
screening.
Isolate MIC (mg/l) Gene
a
ITZ VOR POS hypoth. erg6 hapE erg25 alpha. C2H2
47–169 parent 0.25 0.5 0.063 2 2 2 2 2 2
isolate 3 parent .16 4 0.5 + + + + + +
isolate 4 parent .16 4 0.5 + + + + + +
v121-42 progeny (47–169 x
isolate 3)
.16 2 0.5 2 + + 2 2 +
v121-43 progeny (47–169 x
isolate 3)
.16 2 0.5 2 + + + 2 2
v121-54 Progeny (47–169 x
isolate 3)
.16 2 0.5 + + + + 2 2
v121-55 progeny (47–169 x
isolate 3)
.16 2 0.5 2 + + 2 2 2
v121-59 progeny (47–169 x
isolate 3)
.16 2 0.5 2 + + 2 2 2
v121-74 progeny (47–169 x
isolate 3)
.16 4 0.5 2 + + 2 + +
v121-78 progeny (47–169 x
isolate 3)
.16 2 0.5 2 + + 2 + 2
v122-02 progeny (47–169 x
isolate 4)
.16 2 0.5 2 + + + + 2
v122-08 progeny (47–169 x
isolate 4)
.16 4 0.5 2 + + + + 2
v122-12 progeny (47–169 x
isolate 4)
.16 2 0.25 2 2 + 2 2 2
v122-13 progeny (47–169 x
isolate 4)
.16 4 0.5 2 + + + + 2
v122-17 progeny (47–169 x
isolate 4)
.16 2 0.25 2 2 + 2 + 2
v122-18 progeny (47–169 x
isolate 4)
.16 2 0.5 2 2 + + 2 2
a‘2’ indicates absence of the mutation, ‘+’ indicates presence of the mutation.
doi:10.1371/journal.pone.0050034.t005
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AFUB_098170 and AFUA_8G02440/AFUB_084150; as deter-
mined by the CADRE genome browser [62,63] and literature
[64,65]). Both genes function downstream of the cyp51 (erg11) gene,
at least in Saccharomyces cerevisiae [66]. It has been shown that
downstream genes erg3 [29,31,37,67], erg6, and erg28 [67] are
involved in resistance in other fungi. In addition, erg6 and erg25 are
both up-regulated in amphotericin B/fluconazole resistant C.
albicans, suggesting a possible role of these two genes in acquired
resistance [68]. Neither erg6 nor erg25 have ever been described to
impact on azole susceptibility in A. fumigatus, but many erg genes,
amongst which erg25, have been shown to be differentially
expressed after voriconazole exposure [69]. Nevertheless, we
found no evidence that the mutations in either erg6 or erg25 are
associated with the resistant phenotype in isolates 3 and 4; neither
from the sexual crossing- nor from the transformation experi-
ments. In addition, the erg6/erg25 double mutation was found in
azole susceptible progeny, excluding the possibility that both
mutations together would result in the resistant phenotype (results
not shown).
The hapE gene encodes the CCAAT-binding factor complex
subunit HapE. Besides HapE, the CCAAT-binding complex
(Hap-complex) consists of at least two other subunits: HapB and
Table 6. Microsatellite typing results of the resistant progeny.
Isolate Microsatellite Microsatellite genotype
3A 3B 3C 4A 4B 4C
47–169 parent 16 10 24 11 14 9 A
isolate 3 parent 47 13 13 7 9 10 B
isolate 4 parent 47 13 13 7 9 10 B
v121-42 progeny (47–169 x isolate 3) 16 13 24 7 9 9 C
v121-43 progeny (47–169 x isolate 3) 16 13 13 7 9 10 D
v121-54 progeny (47–169 x isolate 3) 16 13 13 7 14 10 E
v121-55 progeny (47–169 x isolate 3) 16 13 24 7 9 10 F
v121-59 progeny (47–169 x isolate 3) 16 13 13 11 14 10 G
v121-74 progeny (47–169 x isolate 3) 16 13 13 7 9 9 H
v121-78 progeny (47–169 x isolate 3) 16 13 24 7 14 10 I
v122-02 progeny (47–169 x isolate 4) 16 13 24 7 9 9 C
v122-08 progeny (47–169 x isolate 4) 47 13 13 7 14 9 J
v122-12 progeny (47–169 x isolate 4) 47 13 13 7 14 10 K
v122-13 progeny (47–169 x isolate 4) 47 13 24 7 9 10 L
v122-17 progeny (47–169 x isolate 4) 47 10 24 7 9 9 M
v122-18 progeny (47–169 x isolate 4) 47 13 13 7 9 9 N
doi:10.1371/journal.pone.0050034.t006
Figure 2. In vitro growth curves of susceptible and resistant progeny. A. In vitro growth curves of susceptible (n = 12) and resistant (n = 4)
progeny. B. The maximum growth per hour during the exponential phase of the growth curve (6–10 hours, between dashed lines of Figure 2A) was
averaged (6standard deviation) for susceptible and resistant progeny. The difference is significant according to a Student’s T-test (one-tailed,
heteroscedastic).
doi:10.1371/journal.pone.0050034.g002
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HapC. The complex is a transcription factor that specifically
recognizes the regulatory CCAAT element found in the forward
or reverse orientation in promoter regions of numerous eukaryotic
genes [70]. The hapE gene contains four exons and the mutation is
situated in the fourth exon, in the evolutionary conserved core
domain [62,63,71], suggesting that P88 is an important amino
acid for the function of the protein. Moreover, in the human NF-
YC (the mammalian HapE homologue) deletion of residues 43–45
(homologous to A. fumigatus residues 87–89), are deleterious for
DNA binding [72], indicating that P88 is needed for the Hap-
complex to bind the regulatory CCAAT element and initiate
transcription.
Initially, we hypothesized that the resistance observed in the
HapE-mutant might be HapX-mediated. HapX has been shown
to physically interact with the Hap-complex (as shown in A.
nidulans [73]) and is important in adaptation to conditions of iron
starvation. Conversely, in conditions of iron sufficiency, HapX
expression is repressed [65]. HapX deficiency causes significant
attenuation of virulence in a murine model of aspergillosis [65]. As
our resistant patient isolates also showed reduced virulence [46],
we tested the isolates for their azole susceptibility in the presence
and absence of iron to investigate whether the resistance (and
attenuated virulence) observed could be HapX-mediated. How-
ever, our results indicated that the presence of iron did not have
any effect on susceptibility (results not shown), suggesting that
resistance may not be mediated by HapX.
We have previously observed that the cyp51A expression level of
isolates 3 and 4 was four to six-fold higher compared to isolates 1
and 2 [46]. In addition, analysis of the sexual progeny showed that
the hapE mutant has an increased cyp51A mRNA expression
compared to progeny without the hapE mutation. As Hap is a
transcription factor complex, the increased resistance might be due
to a gain of function mutation if the mutated Hap-complex binds
to a CCAAT-box in the promoter region of cyp51A and induces
the expression of the gene. Alternatively, Hap might function as a
transcriptional repressor, and the HapE P88L substitution could
de-repress cyp51A expression. A CCAAT-box is present in the 59
upstream region of A. fumigatus cyp51A, located at 2197 bp from
the start codon, though additional analyses are needed to confirm
the binding of the (mutated) Hap-complex. Gain-of-function
mutations in transcription factors have already been shown to be
linked to increased antifungal drug resistance in C. albicans [74–
79].
The NF-Y (the mammalian Hap-complex)/SREBP (sterol-
regulatory element binding protein) combination regulates essen-
tially all genes involved in cholesterol metabolism [80], indicating
that the fungal ergosterol biosynthesis (the pathway analogous to
the mammalian cholesterol biosynthesis), may also be mediated by
these regulators. An in vitro null-mutant of the A. fumigatus SREBP
transcription factor SrbA has recently been shown to be highly
susceptible to fluconazole and voriconazole [45]. A subsequent
study suggested that the increased fluconazole susceptibility in the
absence of SrbA was partially due to loss of iron homeostasis [81].
Furthermore, SrbA is a direct transcriptional regulator of cyp51A,
being the likely underlying mechanism of the increased suscepti-
bility of the deletion mutant [82]. It currently remains unclear
whether the declined expression is indeed the cause of the
increased azole susceptibility and there has been no evidence for
involvement of SrbA in resistance in clinical cases. However, these
data indicate that alterations in SREBP transcription factors such
as SrbA or NF-Y (Hap) transcription factor subunits such as HapE
may indeed initiate changes altering cyp51A expression and
subsequently lead to azole resistance.
In conclusion, by combining a comparative genomic and
genetic approach, we have discovered a novel triazole resistance
mutation in A. fumigatus caused by a single base substitution in the
transcription factor subunit HapE. We were fortunate to have a set
of isogenic strains, i.e. isolates with a similar genetic background,
and a comparison of the whole genome sequences of isolates 2 and
3 shortlisted 69 potential non-synonymous mutations. Through
resequencing of candidate mutations, and the addition of sexual
crosses, we were able to significantly reduce the selection of
candidate mutations for the azole resistant phenotype.
Over the last decade, an increase of azole resistance in A.
fumigatus isolates has been observed [9–12]. Importantly, patients
suffering from azole-resistant Aspergillus disease may fail to respond
to therapy [11,13–19]. Insight in the mutations that cause
resistance can help to understand the epidemiology, find new
targets for antifungal compounds and to develop diagnostic tools.
The need to identify resistance mechanisms was underscored in a
recent paper estimating that in 54% of patients with an azole
resistant A. fumigatus isolate the resistance mechanism was not
Cyp51A-mediated and thus remained unexplained [9]. This is a
challenge for the early diagnosis of azole-resistance in patients with
Aspergillus diseases. In these patients fungal cultures often remain
negative, which precludes in vitro susceptibility testing. Further-
more, a recent study showed that the use of molecular tools for
Figure 3. Cyp51A mRNA levels in the parental isolates (47–169,
isolate 3, isolate 4) and three of the progeny (v122-12, v121-
64, v121-48). Isolate v122-12 contains only the HapE substitution and
not the other five gene mutations. As a control, we selected two other
progeny: v121-64 containing only the erg25 mutation and v121-48
containing the erg6/erg25 double mutation. S: susceptible, R: resistant.
doi:10.1371/journal.pone.0050034.g003
Table 7. MICs of recombinants with either the G54E
substitution in Cyp51A (positive control) or the P88L
substitution in HapE.
Substitutions MIC
Isolate Cyp51A HapE ITZ VOR POS
Transformation
recipient akuBKU80
- - 0.125 0.25 0.032
Positive control
Cyp51A (1)
G54E - .16 0.125 0.5
Positive control
Cyp51A (2)
G54E - .16 0.125 1
HapE (1) - P88L .16 1 0.125
HapE (2) - P88L .16 1 0.125
MIC, minimum inhibitory concentration; ITZ, itraconazole; VOR, voriconazole;
POS, posaconazole.
doi:10.1371/journal.pone.0050034.t007
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detection of cyp51A-mutations directly in clinical specimens was
much more sensitive than culture [83]. However, knowledge of
underlying resistance mechanisms is required in order to apply
molecular techniques in patient care. The strategy that we have
described will help to identify resistance mechanisms and improve
our diagnostic tools in order to ultimately improve the outcome of
patients with azole resistant Aspergillus diseases.
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